Determination of Serum Interleukin-36 Alpha, Beta, Gamma and Interleukin-17 Levels in Patients with Multiple Myeloma

Nesibe Yıldız Bilge; Hatice Terzi; Halef Okan Dogan; Demet Kablan; Mehmet Şencan

doi:10.7197/cmj.1431762

EN TR

Determination of Serum Interleukin-36 Alpha, Beta, Gamma and Interleukin-17 Levels in Patients with Multiple Myeloma

Abstract

Objective: Multiple myeloma (MM) is a hematologic malignancy characterized by bone marrow infiltration of clonal plasma cells. Today, there is no treatment for obtaining a complete cycle for MM. IL-36 is a cytokine composed of three agonists named alpha, beta, and gamma. Its increase in inflammation has been proven in the literature. It is also reported that IL-17 plays a role in some rheumatologic and malignant diseases together with inflammation. Methods: The aim of the study is to figure out the roles, if any, of IL-36 and IL-17 in the pathogenesis of MM depending on their known physiology and to contribute to the literature to find new treatment options. 33 newly diagnosed MM patients who had never received any treatment and 33 healthy volunteers were included in the study. Basic laboratory parameters and interleukin levels in myeloma patient group and healthy group were included in the study. Results: In the study, it was found that IL-36 alpha, beta, gamma, and IL-17 levels were statistically significantly lower in the disease group when compared to the healthy group. A negative correlation was found between IL-17 measurement and beta-2 microglobulin. Therefore, it was thought that IL-17 may be a marker to predict prognosis. Conclusion: In conclusion, we think that IL-36 and IL-17 may play a role in the etiopathogenesis of MM and IL-36 alpha and IL-17 may be associated with prognosis. However, there is a need for more comprehensive studies.

Keywords

Multipl Myelomali Hastalarda Serum İnterlökin-36 Alfa, Beta, Gama; İnterlökin-17 Düzeyinin Belirlenmesi

Öz

Amaç: Multipl myelom (MM), klonal plazma hücrelerinin kemik iliği infiltrasyonu ile karakterize hematolojik bir malignitedir. Günümüzde halen MM için tam kür elde edecek tedavi yoktur. IL-36; alfa, beta ve gama isimli üç agonistten oluşan bir sitokindir. İnflamasyondaki artışı literatürde kanıtlanmıştır. IL-17’nin ise inflamasyonla birlikte bazı romatolojik ve malign hastalıklarda rol oynadığı literatürde bildirilmiştir. Yöntem: Bizim amacımız IL-36 ve IL-17’nin bilinmekte olan fizyolojilerinden yola çıkarak MM patogenezindeki rollerini anlayabilmek, yeni tedavi seçenekleri bulunabilmesi için literatüre katkı sağlamaktır. Çalışmamıza 33 yeni tanı hiç tedavi almamış MM hastası ve 33 sağlıklı gönüllü alındı. Myelom hasta grubu ve sağlıklı grupta temel laboratuvar parametreleri, interlökin düzeyleri çalışmaya dahil edildi. Bulgular: Çalışmamızda IL-36 alfa, beta, gama ve IL-17 düzeyi sağlıklı gruba göre hastalıklı grupta istatiksel olarak anlamlı şekilde düşük saptandı. IL-17 ölçümü ile beta-2 mikroglobulin arasında negatif yönlü bir ilişki bulduk. Bu nedenle IL-17 nin prognozu öngörmede bir belirteç olabileceğini düşündük. Sonuç: Sonuç olarak, IL-36 ve IL-17’nin MM etiyopatogenezinde rolü olabileceğini, IL-36 alfa ve IL-17’nin prognoz ile ilişkili olabileceğini düşünüyoruz. Ancak daha geniş kapsamlı çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Supporting Institution

CÜBAP

Project Number

T-2022-973

Ethical Statement

The present study was conducted with the approval of Sivas Cumhuriyet University Interventional Clinical Trials Ethics Committee (Decision No: 2022-02/01).

References

Firth J. Haematology: multiple myeloma. Clin Med (Lond). Ocak 2019;19(1):58-60.
Brigle K, Rogers B. Pathobiology and Diagnosis of Multiple Myeloma. Seminars in Oncology Nursing. 01 August 2017;33(3):225-36.
Zhou L, Todorovic V. Interleukin-36: Structure, Signaling and Function. Adv Exp Med Biol. 2021;21:191-210.
Gresnigt MS, van de Veerdonk FL. Biology of IL-36 cytokines and their role in disease. Semin Immunol. 15 Dec 2013;25(6):458-65.
Melton E, Qiu H. Interleukin-36 Cytokine/Receptor Signaling: A New Target for Tissue Fibrosis. Int J Mol Sci. 04 September 2020;21(18):6458.
Yazdi AS, Ghoreschi K. The Interleukin-1 Family. Adv Exp Med Biol. 2016;941:21-9.
Walsh PT, Fallon PG. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases. Ann N Y Acad Sci. April 2018;1417(1):23-34.
Yan JW, Wang YJ, Peng WJ, Tao JH, Wan YN, Li BZ, Mei B, Chen B, Yao H, Yang GJ, Li XP, Ye DQ, Wang J. Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases. Expert Opin Ther Targets. January 2014;18(1):29-41.

Amatya N, Garg AV, Gaffen SL. IL-17 Signaling: The Yin and the Yang. Trends in Immunology. 01 May 2017;38(5):310-22
Ritzmann F, Lunding LP, Bals R, Wegmann M, Beisswenger C. IL-17 Cytokines and Chronic Lung Diseases. Cells. Ocak 2022;11(14):2132.
Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 25 Fab 2011;34(2):149-62.
Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. Mayıs 2010;7(3):164-74.
Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311-21.
McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 16 Nisan 2019;50(4):892-906.
Türk Hematoloji Derneği Multipl Myelom Tanisi Ve Tedavi Kilavuz. Galenos Yayınevi, Mart-2020.
Hussain A, Almenfi HF, Almehdewi AM, Hamza MS, Bhat MS, Vijayashankar NP. Laboratory Features of Newly Diagnosed Multiple Myeloma Patients. Cureus. 22 May 2019;11(5):e4716.
Cai Y, Zhao , Dai Q, Xu M, Xu X, Xia W. Prognostic value of the albumin-globulin ratio and albümin globulin score in patients with multiple myeloma. J Int Med Res. March 2021;49(3):300060521997736.
Dong H, Hao Y, Li W, Yang W, Gao P. IL-36 Cytokines: Their Roles in Asthma and Potential as a Therapeutic. Front Immunol. 2022;13:921275.
Scheibe K, Kersten C, Schmied A, Vieth M, Primbs T, Carlé B, Knieling F, Claussen J, Klimowicz AC, Zheng J, Baum P, Meyer S, Schürmann S, Friedrich O, Waldner MJ, Rath T, Wirtz S, Kollias G, Ekici AB, Atreya R, Raymond EL, Mbow ML, Neurath MF, Neufert C. Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation. Gastroenterology. 01 March 2019;156(4):1082-1097.e11
Nishida A, Hidaka K, Kanda T, Imaeda H, Shioya M, Inatomi O, Bamba S, Kitoh K, Sugimoto M, Andoh A. Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 01 February 2016;22(2):303-14.
Chen W jian, Yu X, Yuan XR, Chen B jie, Cai N, Zeng S, Sun Y song, Li H wen. The Role of IL-36 in the Pathophysiological Processes of Autoimmune Diseases. Front Pharmacol. 2021 Oct 5;12:727956.
Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, Kahlenberg JM, Harms PW, Gudjonsson JE. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. Journal of Allergy and Clinical Immunology. 01 Temmuz 2017;140(1):109-20.
Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. British Journal of Dermatology. 01 Ocak 2014;170(1):202-4.
Burden AD. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis. Expert Review of Clinical Immunology. 04 Mayıs 2023;19(5):473-81.
El-Awaisi J, Kavanagh DPJ, Rink MR, Weston CJ, Drury NE, Kalia N. Targeting IL-36 improves age-related coronary microcirculatory dysfunction and attenuates myocardial ischemia/reperfusion injury in mice. JCI Insight. 2022 Mar 8;7(5):e155236.
Baker KJ, Buskiewicz E, Finucane M, Chelliah A, Burke L, Houston A, Brint E. IL-36 expression is increased in NSCLC with IL-36 stimulation of lung cancer cells promoting a pro-tumorigenic phenotype. Cytokine. 01 Mayıs 2023;165:156170.
Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC. Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunol Immunother. 01 November 2013;62(11):1675-85.
Chen F, Qu M, Zhang F, Tan Z, Xia Q, Hambly BD, Bao S, Tao K. IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? BMC Cancer. 03 Fabruary 2020;20(1):92.
Wang X, Zhao X, Feng C, Weinstein A, Xia R, Wen W, Lv Q, Zuo S, Tang P, Yang X, Chen X, Wang H, Zang S, Stollings L, Denning TL, Jiang J, Fan J, Zhang G, Zhang X, Zhu Y, Storkus W, Lu B. IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. Cancer Cell. 14 September 2015;28(3):296-306.
Chen Y, Sun J, Huang Y, Liu Y, Liang L, Yang D, Lu B, Li S. Targeted codelivery of doxorubicin and IL-36γ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis. Nanomedicine: Nanotechnology, Biology and Medicine. 01 Jan 2019;15(1):129-41.
Le N, Luk I, Chisanga D, Shi W, Pang L, Scholz G, Mariadason J, Ernst M, Huynh J. IL-36G promotes cancer-cell intrinsic hallmarks in human gastric cancer cells. Cytokine. 01 July 2022;155:155887.
Guo HZ, Guo ZH, Yu SH, Niu LT, Qiang WT, Huang MM, Tian YY, Chen J, Yang H, Weng XQ, Zhang Y, Zhang W, Hu SY, Shi J, Zhu J. Leukemic progenitor cells enable immunosuppression and post-chemotherapy relapse via IL-36–inflammatory monocyte axis. Science Advances. 08 October 2021;7(41):eabg4167.
Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O’Toole M, Young DA, Fouser LA, Nickerson-Nutter C, Collins M, Dunussi-Joannopoulos K, Medley QG. Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis. Journal of Investigative Dermatology. 01 Dec 2011;131(12):2428-37.
Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. October 2016;15(10):1413-20.
Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG. Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis. Journal of Investigative Dermatology. 01 March 2011;131(3):677-87.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860–7.
Zhang Q, Liu S, Ge D, Xue Y, Xiong Z, Abdel-Mageed AB, Myers L, Hill SM, Rowan BG, Sartor O, Melamed J, Chen Z, You Z. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res. 2012; 72:2589– 99.
Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009; 15:1016–22.
Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogeninduced skin cancer. Cancer Res. 2010; 70:10112–20.
Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, Shyr Y, Moses HL. TGF-beta Receptor II Loss Promotes Mammary Carcinoma Progression by Th17 Dependent Mechanisms. Cancer Discov. 2011; 1:430–41.
Xu B, Guenther JF, Pociask DA, Wang Y, Kolls JK, You Z, Chandrasekar B, Shan B, Sullivan DE, Morris GF. Promotion of lung tumor growth by interleukin-17. Am J Physiol Lung Cell Mol Physiol. 2014; 307:L497–508.
McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, Sears CL, Pardoll DM, Leach SD. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 2014; 25:621–37.
Zhang Q, Liu S, Parajuli KR, Zhang W, Zhang K, Mo Z, Liu J, Chen Z, Yang S, Wang AR, Myers L, You Z. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene. Fabruary 2017;36(5):687-99.
Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003; 101:2620–7.
Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 09 July 2009;114(2):357-9.
Chen J gao, Xia J chuan, Liang X ting, Pan K, Wang W, Lv L, Zhao JJ, Wang OJ, Li YQ, Chen S, He J, Huang LX, Ke ML, Chen YB, Ma HQ, Zeng ZW, Zhou ZW, Chang AE, Li Q. Intratumoral Expression of IL-17 and Its Prognostic Role in Gastric Adenocarcinoma Patients. Int J Biol Sci. 11 January 2011;7(1):53-60.
Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism. Blood. 15 March 2002;99(6):2114-21.
Bankir M, Acik DY. IL-17 and IL-23 levels in patients with early-stage chronic lymphocytic leukemia. North Clin Istanb. 20 November 2020;8(1):24-30.
Tang D, Niu Q, Jiang N, Li J, Zheng Q, Jia Y. Increased frequencies of Th17 in the peripheral blood of patients with chronic lymphocytic leukemia: A one year follow-up. Pak J Med Sci. 2014;30(5):1128-33.
Alexandrakis MG, Pappa CA, Miyakis S, Sfiridaki A, Kafousi M, Alegakis A, Stathopoulos EN. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. European Journal of Internal Medicine. 01 October 2006;17(6):412-6.
Lemancewicz D, Bolkun L, Jablonska E, Czeczuga-Semeniuk E, Kostur A, Kloczko J, Dzieciol J. The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients. Med Sci Monit. 01 January 2012;18(1):BR54-9.

Details

Primary Language

English

Subjects

Health Services and Systems (Other)

Journal Section

Research Article

Authors

Nesibe Yıldız Bilge
0000-0002-8207-1085
Türkiye

Hatice Terzi ^*
0000-0003-3471-1305
Türkiye

Halef Okan Dogan
0000-0001-8738-0760
Türkiye

Demet Kablan
0000-0002-3988-4603
Türkiye

Mehmet Şencan
0000-0002-1459-3906
Türkiye

Publication Date

March 29, 2024

Submission Date

February 6, 2024

Acceptance Date

March 23, 2024

Published in Issue

Year 2024 Volume: 46 Number: 1

DOI

https://doi.org/10.7197/cmj.1431762

IZ

https://izlik.org/JA58FA97LW

Cite

RIS / Bibtex

AMA

1.Yıldız Bilge N, Terzi H, Dogan HO, Kablan D, Şencan M. Determination of Serum Interleukin-36 Alpha, Beta, Gamma and Interleukin-17 Levels in Patients with Multiple Myeloma. CMJ. 2024;46(1):57-65. doi:10.7197/cmj.1431762